Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial

INTRODUCTION: Azathioprine (AZA) interferes with the activation of T and B lymphocytes, which are the main cells involved in the pathogenesis of Graves’ disease (GD). The aim of this study was to investigate the effectiveness of AZA as an adjuvant therapy to antithyroid drugs (ATDs) for moderate and...

Descripción completa

Detalles Bibliográficos
Autores principales: Allam, Magdy Mohamed, El-Zawawy, Hanaa Tarek, Kader Okda, Amr Abdel, Ali Alshaikh, Ayoub, Ghazy, Ramy Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319122/
https://www.ncbi.nlm.nih.gov/pubmed/37409226
http://dx.doi.org/10.3389/fendo.2023.1168936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319122/
https://www.ncbi.nlm.nih.gov/pubmed/37409226
http://dx.doi.org/10.3389/fendo.2023.1168936

Ejemplares similares